期刊文献+

血清胱抑素C和甲状旁腺激素以及肾功能三项在终末期肾病患者诊断中的临床价值

Clinical Value of Serum Cystatin C,Parathyroid Hormone and Renal Function in Patients with End-stage Renal Disease
下载PDF
导出
摘要 目的分析血清胱抑素C和甲状旁腺激素以及肾功能3项在终末期肾病(End-stage renal disease,ESRD)患者诊断中的临床价值。方法选取江苏省泰州市姜堰中医院2019年1月至2020年7月收治的早期肾病患者、终末期肾病患者和同期体检的健康人员作为本次研究对象,各32例。分别设定为早期病组、终末期组和健康组。检测3组患者的血清胱抑素C(CysC)、甲状旁腺激素(PTH)和血清尿素氮(BUN)、尿酸(UA)、肌酐(Cr)指标,并对比、分析各项指标在终末期肾病患者诊断中的临床价值。结果健康组的CysC、PTH、BUN和CR指标均<早期组<终末期组(P<0.05);终末期组和早期组的UA指标明显高于健康组,差异有统计学意义(P<0.05);但终末期组和早期组的UA指标对比差异无统计学意义(P>0.05)。联合检测在早期组和终末组中的阳性检出率明显高于各个单项检测,差异有统计学意义(P<0.05);联合检测各项阳性检出率与健康组相比差异无统计学意义(P>0.05)。结论CysC、PTH和BUN、UA、Cr指标在肾病患者和健康组患者比较均具有明显差异,各项指标联合检测具有较高阳性检出率,在终末期肾脏病临床诊断中具有较高应用价值。 Objective To analyze the clinical value of serum cystatin C,parathyroid hormone and renal function in the diagnosis of end stage renal disease(ESRD).Methods The patients with early kidney disease,end-stage kidney disease and healthy personnel who received physical examination during the same period from January 2019 to July 2020 in Jiangyan Hospital of Traditional Chinese Medicine were selected as the subjects of this study,32 cases each.They were divided into the early disease group,the end-stage group and the healthy group.Serum cystatin C(CysC),parathyroid hormone(PTH)and serum urea nitrogen(BUN),uric acid(UA)and creatinine(Cr)were measured in 3 groups of patients,and the clinical value of each indicator in the diagnosis of end-stage renal disease was compared and analyzed.Results The CysC,PTH,bun and Cr indexes of non nephrotic group were all<early group<end stage group(P<0.05);UA index of end-stage group and early group was significantly higher than that of non nephropathy group,the difference was statistically significant(P<0.05),but there was no significant difference in UA index between end-stage group and early group(P>0.05).The positive detection rate of combined detection in early group and terminal group was significantly higher than that of single detection,and the difference was statistically significant(P<0.05);the positive detection rate of combined detection in non nephropathy group had no significant difference(P>0.05).Conclusion CysC,PTH and bun,UA,Cr indicators in patients with kidney disease and non kidney disease have significant differences,the combined detection of various indicators has a high positive detection rate,which has high application value in the clinical diagnosis of end-stage renal disease.
作者 周春萍 陈凯丽 缪亚梅 ZHOU Chunping;CHEN Kaili;MIAO Yamei(Jiangyan Hospital of Traditional Chinese Medicine,Taizhou,Jiangsu 225500,China)
出处 《大医生》 2020年第21期97-100,共4页 Doctor
关键词 血清胱抑素C 甲状旁腺激素 肾功能三项 终末期肾病 CysC PTH three items of renal function end-stage renal disease
  • 相关文献

参考文献14

二级参考文献139

  • 1何煜,张琰,廖婷婷,龚俊,罗韦峰,夏宁.老年早期糖尿病肾病患者血清胱抑素C与氧化应激的相关性[J].中国老年学杂志,2014,34(3):594-596. 被引量:18
  • 2章毅,王永志.根据血清胱抑素C浓度推测肾小球滤过率的临床应用[J].中国血液净化,2004,3(12):655-656. 被引量:52
  • 3Goodman WG,Goldin J,Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.N Engl J Med,2000,342(20) ; 1478-1483.
  • 4Kidney Disease : Improving Global Outcomes ( KDIGO ) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation,prevention,and treatment of Chronic Kidney Disease-Mineral and Bone Disorder ( CKD-MBD ). Kidney Int Suppl,2009, (113) :SM30.
  • 5National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis,2003,42(4 Suppl 3) :S1-201.
  • 6Uhiig K, Bems JS, Kestenbaum B,et al. K/DOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation,and Treatment of CKD-Mineral and Bone Disorder ( CKD-MBD).Am J Kidney Dis,2010,55(5) :773-799.
  • 7Gardham C,Stevens PE, Delaney MP, et al. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol, 2010,5(7); 1261-1267.
  • 8Berson SA,Yalow RS,Aurbach GD,et al.Immunoassay of bovine and human parathyroid hormone.Proc Natl Acad Sci U S A, 1963,49(5): 613-617.
  • 9Lepage R, Roy L, Brossard JH, et al. A non-( 1-84 ) circulating parathyroid hormone ( PTH ) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem,1998,44(4) ;805-809.
  • 10Terry AH,Orrock J,Meikle AW. Comparison of two third-generation parathyroid hormone assays.Clin Chem, 2003,49 (2 ) : 336-337.

共引文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部